NYSE: NVSNovartis Ag Stock
$121.02-2.71 (-2.19%)
Updated Jul 11, 2025
NVS Price
$121.02
Fair Value Price
N/A
Market Cap
$237.11B
52 Week Low
$96.06
52 Week High
$124.83
P/E
18.79x
P/B
6.18x
P/S
4.12x
PEG
1.32x
Dividend Yield
3.2%
Revenue
$53.22B
Earnings
$12.86B
Gross Margin
75.7%
Operating Margin
30.01%
Profit Margin
24.2%
Debt to Equity
1.6
Operating Cash Flow
$19B
Beta
0.35
Next Earnings
Jul 17, 2025
Ex-Dividend
N/A
Next Dividend
N/A
NVS Overview
Novartis AG manufactures prescription medications related to oncology, ophthalmology, neuroscience, immunology, respiratory, and cardio-metabolic medicine. Novartis AG is collaborating with Alnylam Pharmaceuticals to commercialize inclisiran. The company is also collaborating with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine NVS's potential to beat the market
AStrong Buy
- Stocks with a Zen Rating of Strong Buy (A) had an average return of +32.52% per year. Learn More
Zen Rating Component Grades
B
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: General Drug Manufacturer
Industry Rating
A
NVS
Ranked#1 of 18
Ranked#1 of 18
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $156.90 | A | |
| $9.74 | A | |
| $109.64 | B |
Be the first to know about important NVS news, forecast changes, insider trades & much more!
NVS News
Overview
Due Diligence Score
–
Industry Average (44)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NVS scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NVS ($121.02) is trading above its intrinsic value of $68.26, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
NVS is good value based on its earnings relative to its share price (18.79x), compared to the US market average (30.99x)
P/E vs Market Valuation
NVS is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more NVS due diligence checks available for Premium users.
Valuation
NVS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
18.79x
Industry
38.63x
Market
30.99x
NVS is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
NVS is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
NVS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.18x
Industry
6.05x
NVS is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NVS price to earnings growth (PEG)
For valuing profitable companies with growth potential
NVS is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
NVS's financial health
Profit margin
Revenue
$13.6B
Net Income
$3.6B
Profit Margin
26.5%
NVS's Earnings (EBIT) of $15.97B... subscribe to Premium to read more.
Interest Coverage Financials
NVS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$99.9B
Liabilities
$61.5B
Debt to equity
1.6
NVS's short-term liabilities ($31.62B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NVS's long-term liabilities ($29.87B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NVS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
NVS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$3.6B
Investing
$330.0M
Financing
-$8.5B
NVS's operating cash flow ($19.00B)... subscribe to Premium to read more.
Debt Coverage Financials
NVS vs General Drug Manufacturer Stocks
Novartis Ag Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.